About Deciphera Pharmaceuticals (NASDAQ:DCPH)
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400
Debt
Debt-to-Equity Ratio0.01%
Current Ratio14.35%
Quick Ratio14.35%
Price-To-Earnings
Trailing P/E Ratio-7.65
Forward P/E Ratio-9.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.64 per share
Price / Book4.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees65
Outstanding Shares32,590,000
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals (NASDAQ:DCPH) released its earnings results on Wednesday, March, 28th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.19. View Deciphera Pharmaceuticals' Earnings History.
What price target have analysts set for DCPH?
6 brokerages have issued 12 month price objectives for Deciphera Pharmaceuticals' stock. Their predictions range from $30.00 to $57.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $43.3333 in the next twelve months. View Analyst Ratings for Deciphera Pharmaceuticals.
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include Array BioPharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec A.G. (EVTCY), Ascendis Pharma (ASND), Clovis Oncology (CLVS), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA) and Global Blood Therapeutics (GBT).
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor Ph.D., CEO, Pres & Director (Age 63)
- Dr. Oliver Rosen M.D., Chief Medical Officer (Age 54)
- Mr. Christopher J. Morl M.B.A., B.Sc. (Hons), Chief Bus. Officer (Age 59)
- Dr. Daniel L. Flynn Ph.D., Founder & Chief Scientific Officer (Age 63)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
When did Deciphera Pharmaceuticals' lock-up period expire?
Deciphera Pharmaceuticals' lock-up period expired on Tuesday, March 27th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its IPO on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. Since the end of Deciphera Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
Media headlines about DCPH stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also gave news stories about the company an impact score of 46.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $22.56.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $754.23 million. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings History and Estimates Chart
Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings Estimates
2018 EPS Consensus Estimate: ($2.76)
2019 EPS Consensus Estimate: ($3.34)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.62) | ($0.62) | ($0.62) |
| Q2 2018 | 1 | ($0.66) | ($0.66) | ($0.66) |
| Q3 2018 | 1 | ($0.71) | ($0.71) | ($0.71) |
| Q4 2018 | 1 | ($0.77) | ($0.77) | ($0.77) |
| Q1 2019 | 1 | ($0.79) | ($0.79) | ($0.79) |
| Q2 2019 | 1 | ($0.82) | ($0.82) | ($0.82) |
| Q3 2019 | 1 | ($0.85) | ($0.85) | ($0.85) |
| Q4 2019 | 1 | ($0.88) | ($0.88) | ($0.88) |
Deciphera Pharmaceuticals (NASDAQ DCPH) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/28/2018 | Q4 2017 | ($0.4270) | ($0.62) | | | View | N/A |  |
| 11/14/2017 | Q3 2017 | ($0.5450) | ($5.85) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Deciphera Pharmaceuticals (NASDAQ:DCPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.61%
Institutional Ownership Percentage: 48.20%
Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/2/2017 | New Leaf Venture Management Ii | Major Shareholder | Buy | 375,000 | $17.00 | $6,375,000.00 | | |
(Data available from 1/1/2013 forward)
Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 25 at 4:29 PM |
 | Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in ...
www.businesswire.com - April 17 at 4:42 PM |
| Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents
finance.yahoo.com - April 17 at 9:58 AM |
 | -$0.64 Earnings Per Share Expected for Deciphera Pharmaceuticals (DCPH) This Quarter
www.americanbankingnews.com - April 16 at 11:14 AM |
| Deciphera Pharmaceuticals (DCPH) Upgraded at BidaskClub
www.americanbankingnews.com - April 12 at 10:23 AM |
| Deciphera Pharmaceuticals (DCPH) Coverage Initiated at Instinet
www.americanbankingnews.com - April 6 at 12:23 PM |
| JMP Securities Initiates Coverage on Deciphera Pharmaceuticals (DCPH)
www.americanbankingnews.com - April 6 at 11:00 AM |
| Deciphera Pharmaceuticals (DCPH) Receives New Coverage from Analysts at JPMorgan Chase
www.americanbankingnews.com - April 6 at 11:00 AM |
| Deciphera Pharmaceuticals (DCPH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 4 at 9:36 PM |
| Deciphera Pharmaceuticals Inc (DCPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 7:10 PM |
| Piper Jaffray Analysts Cut Earnings Estimates for Deciphera Pharmaceuticals Inc (DCPH)
www.americanbankingnews.com - April 4 at 7:58 AM |
| Deciphera Pharmaceuticals (DCPH) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 10:36 PM |
| Analysts Expect Deciphera Pharmaceuticals Inc (DCPH) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - March 30 at 1:19 PM |
| BidaskClub Upgrades Deciphera Pharmaceuticals (DCPH) to "Buy"
www.americanbankingnews.com - March 30 at 10:58 AM |
| Deciphera Pharmaceuticals (DCPH) Releases Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM |
| Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - March 28 at 4:16 PM |
| Deciphera Pharmaceuticals Inc's Lock-Up Period Set To End on March 27th (NASDAQ:DCPH)
www.americanbankingnews.com - March 20 at 1:16 AM |
| BidaskClub Lowers Deciphera Pharmaceuticals (DCPH) to Buy
www.americanbankingnews.com - March 17 at 6:14 PM |
 | Deciphera Pharmaceuticals (DCPH) to Report Clinical and Preclinical Data with DCC-2618 at AACR
www.streetinsider.com - March 16 at 9:59 AM |
| Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 9:42 PM |
| Hudson Bay Capital Management LP Raises Holdings in Deciphera Pharmaceuticals Inc (DCPH)
www.americanbankingnews.com - February 28 at 1:54 PM |
| Deciphera Pharma Scores A Sell-Side Recommendation
finance.yahoo.com - February 16 at 4:27 PM |
| Deciphera Pharmaceuticals (DCPH) Coverage Initiated at B. Riley
www.americanbankingnews.com - February 16 at 9:52 AM |
| Deciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 9:24 PM |
| Deciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 10 at 12:14 PM |
| Deciphera Pharmaceuticals (DCPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 11:50 PM |
| Deciphera Pharmaceuticals (DCPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 9 at 8:58 PM |
| Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
finance.yahoo.com - January 4 at 8:49 AM |
| Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:02 AM |
| Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 26 at 12:41 AM |
| Deciphera Pharmaceuticals (DCPH) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 25 at 8:40 PM |
| Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
finance.yahoo.com - December 18 at 8:54 AM |
| Zacks: Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 15 at 5:52 AM |
| Deciphera Pharmaceuticals (DCPH) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - December 8 at 5:14 PM |
| Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 28 at 5:44 PM |
| Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 25 at 11:54 AM |
| Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 21 at 11:50 PM |
 | Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
feeds.benzinga.com - November 21 at 8:00 AM |
| Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
finance.yahoo.com - November 20 at 6:47 PM |
| Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.33 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 18 at 8:00 AM |
| Opening Bell, November 15, 2017
finance.yahoo.com - November 16 at 1:22 PM |
| Deciphera Pharmaceuticals, Inc. (DCPH) Posts Quarterly Earnings Results, Misses Expectations By $5.30 EPS
www.americanbankingnews.com - November 15 at 12:55 PM |
| Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - November 15 at 4:18 AM |
 | Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
globenewswire.com - November 14 at 6:14 PM |
| Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) to Ring The Nasdaq Stock Market Opening Bell
feeds.benzinga.com - November 14 at 11:27 AM |
| Featured Company News - Deciphera Reported Data Analysis from the Ongoing Phase-1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
finance.yahoo.com - November 13 at 12:15 PM |
| Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
finance.yahoo.com - November 10 at 9:10 AM |
| Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
finance.yahoo.com - November 6 at 7:09 PM |
| Analyzing Deciphera Pharmaceuticals (DCPH) & Stemline Therapeutics (STML)
www.americanbankingnews.com - November 6 at 5:31 PM |
| Zacks: Brokerages Set $34.33 Price Target for Deciphera Pharmaceuticals, Inc. (DCPH)
www.americanbankingnews.com - November 3 at 7:50 PM |
Deciphera Pharmaceuticals (NASDAQ:DCPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Deciphera Pharmaceuticals (NASDAQ:DCPH) Income Statement, Balance Sheet and Cash Flow Statement
Deciphera Pharmaceuticals (NASDAQ DCPH) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
